Geoffrey Kuesters Selected Research

Messenger RNA (mRNA)

1/2019

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Geoffrey Kuesters Research Topics

Disease

4	Multiple Sclerosis 10/2017 - 10/2014
3	Neoplasms (Cancer) 11/2020 - 01/2019
2	Relapsing-Remitting Multiple Sclerosis 06/2017 - 01/2017
1	Glioblastoma (Glioblastoma Multiforme) 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2021
1	Breast Neoplasms (Breast Cancer) 11/2020
1	Adenocarcinoma 01/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019
1	Body Weight (Weight, Body) 01/2017

Drug/Important Bio-Agent (IBA)

3	Natalizumab (Tysabri)FDA Link 10/2017 - 01/2017
2	histidine-rich proteinsIBA 11/2020 - 01/2019
2	seribantumabIBA 11/2020 - 01/2019
1	Hormones (Hormone)IBA 11/2020
1	Neuregulin-1 (Neuregulin 1)IBA 01/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019
1	Docetaxel (Taxotere)FDA Link 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	AntibodiesIBA 01/2017
1	IntegrinsIBA 01/2017
1	Immunoglobulins (Immunoglobulin)IBA 01/2017
1	BuffersIBA 10/2016
1	Intravenous Immunoglobulins (IVIG)FDA Link 10/2014

Therapy/Procedure

3	Therapeutics 01/2021 - 10/2017
1	Drug Therapy (Chemotherapy) 01/2019